InvestSMART

Mayne Pharma Group Limited (ASX: MYX) - Share Price

Current share price for MYX : $2.790 0.04 (1.41%)+

Mayne Pharma Group Limited (MYX), an ASX-listed company, is an ASX-listed specialty pharmaceutical company focused on commercializing branded women's health and dermatology pharmaceuticals.

MYX General Information +

ASX Code MYX
Website N/A
Industry/Sector Pharmaceuticals
Market Cap ($M) 227
MYX Share Price $2.800
Day High $2.890
Day Low $2.790
Last Close $2.830
MYX Share Price Movement $0.03 ( 1.06% )
Prices as at 16:01, 14 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Mayne Pharma Group Limited (MYX) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield
Result 2.72¢ 100% 18 Jan 2023 27 Jan 2023 - - -
Interim 1¢ 100% 3 Mar 2011 25 Mar 2011 - - -
Final 2¢ 100% 25 Oct 2010 18 Nov 2010 - - -

See all dividends from Mayne Pharma Group Limited (MYX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Mayne Pharma Group Limited (MYX) price-sensitive announcements

MYX - Mayne Pharma receives $14.4m for legal costs from Cosette
On June 5, 2026, Mayne Pharma Group Limited announced receiving $14.4 million from Cosette
Mayne Pharma Group Limited (MYX)
5 Jun 2026 | 10:44 AM
MYX - Court awards MYX $13.27m for legal costs from Cosette
Mayne Pharma Group Limited has been awarded $13.27 million in legal costs by the Supreme C
Mayne Pharma Group Limited (MYX)
22 May 2026 | 11:08 AM
MYX - Mayne Pharma reports unaudited 3Q FY26 results
Mayne Pharma Group Limited reported its unaudited 3Q FY26 results, highlighting a successf
Mayne Pharma Group Limited (MYX)
29 Apr 2026 | 9:33 AM
MYX - S&P DJI Announces March 2026 Quarterly Rebalance
The document announces the quarterly rebalance of the S&P/ASX indices effective March 23,
Mayne Pharma Group Limited (MYX)
6 Mar 2026 | 5:05 PM

Mayne Pharma Group Limited (MYX) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Mayne Pharma Group Limited (MYX)
ORDINARY FULLY PAID
 Health Care $227 Notification regarding unquoted securities - MYX 7 Jul 2026 8:16AM $2.790 $2.800 risen by 0.36%
Mayne Pharma Group Limited (MYX)
ORDINARY FULLY PAID
 Health Care $227 Notification regarding unquoted securities - MYX 7 Jul 2026 8:16AM $2.790 $2.800 risen by 0.36%
Mayne Pharma Group Limited (MYX)
ORDINARY FULLY PAID
 Health Care $227 Notification regarding unquoted securities - MYX 7 Jul 2026 8:16AM $2.790 $2.800 risen by 0.36%
Mayne Pharma Group Limited (MYX)
ORDINARY FULLY PAID
 Health Care $227 Notification regarding unquoted securities - MYX 7 Jul 2026 8:16AM $2.790 $2.800 risen by 0.36%
Mayne Pharma Group Limited (MYX)
ORDINARY FULLY PAID
 Health Care $227 Initial Director's Interest Notice 1 Jul 2026 9:38AM $2.790 $2.800 risen by 0.36%
Mayne Pharma Group Limited (MYX)
ORDINARY FULLY PAID
 Health Care $227 Mayne Pharma appoints new Non-Executive Director 26 Jun 2026 9:15AM $2.390 $2.800 risen by 17.15%

MYX Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2027F C2 -$27.30 -48.20% 0.00 0.00 0.00% 0.0%
2026F C2 -$52.70 -45.40% 0.00 0.00 0.00% 0.0%
2025A -$76.40 -$96.50 -42.30% 0.00 0.00 0.00% 0.0%

MYX Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2025 A 2026 F 2027 F 2025 A 2026 F 2027 F 2025 A 2026 F 2027 F
Clarity Pharmaceuticals Ltd (CU6) $899M 0.3002 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mayne Pharma Group Limited (MYX) $233M -0.4227 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Neuren Pharmaceuticals Limited (NEU) $2,094M -0.7857 0.0743 1.2000 70.9927 66.0800 30.0364 0.00% 0.00% 0.00%

MYX Directors

Name Position Start Date
Ms Ann Custin Non-Executive Director 23 Mar 2022
Mr David Petrie Non-Executive Director 1 Sep 2022
Ms Meghan Rivera Non-Executive Director 26 Jun 2026
Professor Bruce Gregory Robinson AC Non-Executive Director, Non-Executive Chairman 26 Aug 2014

Mayne Pharma Group Limited (MYX) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
18 Dec 2025 O'BRIEN, Shawn Sell Indirect Shares 129,736 $3.094 $401,341.040
1 Dec 2023 CONDELLA, Frank Buy Direct Shares 7,154 $5.425 $38,811.460
25 Oct 2023 MACFARLANE, Kathryn Buy Direct Shares 18,000 $3.840 $69,120.000

See all changes in directors' interest & trades for Mayne Pharma Group Limited (MYX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

MYX Management

Name Position
Aaron Gray Chief Financial Officer
Laura Loftus Company Secretary

MYX Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Mayne Pharma Group Limited (MYX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
6,743,487 (8.30%) The Goldman Sachs Group, Inc.
5,292,066 (6.51%) Bruce Mathieson
4,986,922 (6.14%) UBS Group AG and its related bodies corporate
4,356,426 (5.36%) Rubric Capital Management LP

MYX Calendar of Events

Date Event
22 February 2027 Report (Interim)
13 October 2026 Report (Annual)
28 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.